ArticleNature cell biology2019
Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening.
Article in Nature cell biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06280560 (Impact of Controlled Ovarian Stimulation and Luteal Phase Support on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation), which is not on this map. Cited by 306 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Controlled Ovarian Stimulation and Luteal Phase Support on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation: Pilot Study
Who cites it
306 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Recent Trends in Tissue Engineering Strategies for Uterine Endometrial Regeneration: a Systematic Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Pooled it
- A systematic review on the culture methods and applications of 3D tumoroids for cancer research and personalized medicine.Cellular oncology (Dordrecht, Netherlands) · 2025Pooled it
- The role of fibrosis in endometriosis: a systematic review.Human reproduction update · 2024Pooled it
- Bioengineering trends in female reproduction: a systematic review.Human reproduction update · 2022Pooled it
- Autologous cell therapy with CD133+ bone marrow-derived stem cells for Asherman Syndrome: a phase 1/2 trial.Nature communications · 2026Trial
- On-chip 3D potency assay for prediction of clinical outcomes for cell therapy candidates for osteoarthritis.Nature communications · 2025Trial
- Gene regulation at the early human maternal-fetal interface.Nature reviews. Genetics · 2026Review
- Organoids: Current Applications and Future Directions.MedComm · 2026Review
- Engineering the human endometrium at the intersection of development and reproduction.Nature biomedical engineering · 2026Review
- Bioinformatics, Machine Learning and Functional Validation Reveal Mitophagy-Related FABP5 and HMOX1 as Diagnostic and Therapeutic Targets in Polycystic Ovary Syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2026Article
- Review
- Simvastatin and Primaquine Identified as Potential Endometriosis Therapeutics via a Novel Epithelial-Stromal Assembloid Drug Screening Assay.bioRxiv : the preprint server for biology · 2026Article
- Review
- Current Perspectives on 2D and 3D Cell Culture Models in Cancer Research: Molecular Determinants of Tumor Biology and Therapeutic Response.Current issues in molecular biology · 2026Review
- Reconstructing the Human EndometriumDevelopment & reproduction · 2026Review
- Bioprinted Human Umbilical Cord Mesenchymal Stem Cell-laden Microfiber-derived Extracellular Vesicles Promote Endometrial Repair and Fertility Recovery in Intrauterine Adhesions.Stem cell reviews and reports · 2026Article
- Patient-derived decidual organoids reveal rhG-CSF-associated protective responses involving JAK2/STAT3 signaling in recurrent spontaneous abortion.Stem cell research & therapy · 2026Article
- Modeling human embryo adhesion using a microfluidic platform.Science advances · 2026Article
- A High-Fidelity and Ancestrally Inclusive Patient-Derived Organoid Platform Resolves Cancer Cell Plasticity in Uterine Carcinosarcoma.bioRxiv : the preprint server for biology · 2026Article
- Patient-derived organoids in gynaecological cancers: emerging tools for therapy and disease modelling.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
246 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial disorders represent a major gynaecological burden. Current research models fail to recapitulate the nature and heterogeneity of these diseases, thereby hampering scientific and clinical progress. Here we developed long-term expandable organoids from a broad spectrum of endometrial pathologies. Organoids from endometriosis show disease-associated traits and cancer-linked mutations. Endometrial cancer-derived organoids accurately capture cancer subtypes, replicate the mutational landscape of the tumours and display patient-specific drug responses. Organoids were also established from precancerous pathologies encompassing endometrial hyperplasia and Lynch syndrome, and inherited gene mutations were maintained. Endometrial disease organoids reproduced the original lesion when transplanted in vivo. In summary, we developed multiple organoid models that capture endometrial disease diversity and will provide powerful research models and drug screening and discovery tools.
Indexed as
Identifiers
31371824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.